Two phase 3 trials of the recently approved IV formulation of secukinumab showed its efficacy vs placebo in treating psoriatic arthritis and axial spondyloarthritis.
Demand for a diabetes medicine called Ozempic is soaring as people take it to shed pounds, leading to shortages in countries including Britain, Germany, Belgium and the United States.